[Pharmacological action of [ethyl p(6-guanidinohexanoyloxy)benzoate] methanesulfonate (FOY)].
General pharmacological effects of [Ethyl p-(6-guanidinohexanoyloxy)benzoate] methanesulfonate (FOY), a new antiproteolytic agent, were studied and the following results were obtained. Acute administration of large doses of FOY in conscious dogs and rabbits caused a decrease in spontaneous motility, ataxia, cyanosis, collapse, mydriasis, and respiratory paralysis. The agent had no effect on the central nervous system and exhibited hypotensive effects in dogs in doses of more than 1 mg/kg. Hypotensive responses were not inhibited by treatment with atropine or hexamethonium. FOY had no effects on ECG in the rabbit at doses of less than 30 mg/kg and at doses from 10(-6) to 10(-4)g/ml, distinctly reduced the amplitude of the spontaneous and rhythmic contractions of the isolated rabbit ileum, guinea-pig ileum and rat uterus preparation. The contractile response to nerve stimulation, noradrenaline and barium was suppressed in isolated guinea-pig vas deferens. FOY had no effects on the twitch response of gastrocnemius muscle to sciatic nerve stimulation in rats. The drug caused local irritant effects in rabbits and rats.
D000109:Acetylcholine / Q000037:antagonists & inhibitors; D000771:Anesthesia, Intravenous; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology; D007611:Aprotinin / Q000494:pharmacology; D001464:Barium / Q000037:antagonists & inhibitors; D001775:Blood Circulation / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D001920:Bradykinin / Q000037:antagonists & inhibitors; D001921:Brain / Q000187:drug effects / Q000502:physiology; D004285:Dogs; D004487:Edema / Q000139:chemically induced; D004837:Epinephrine / Q000037:antagonists & inhibitors; D005260:Female; D006146:Guanidines / Q000494:pharmacology*; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D008698:Mesylates / Q000494:pharmacology; D051379:Mice; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects / Q000502:physiology; D009538:Nicotine / Q000037:antagonists & inhibitors; D010424:Pentobarbital; D010433:Pentylenetetrazole / Q000037:antagonists & inhibitors; D011480:Protease Inhibitors; D011817:Rabbits; D051381:Rats; D012119:Respiration / Q000187:drug effects; D012154:Reticular Formation / Q000187:drug effects / Q000502:physiology; D012702:Serotonin Antagonists; D013331:Strychnine / Q000037:antagonists & inhibitors; D014361:Trypsin Inhibitors / Q000494:pharmacology
D000927:Anticonvulsants; D006146:Guanidines; D006634:Histamine H1 Antagonists; D008698:Mesylates; D011480:Protease Inhibitors; D012702:Serotonin Antagonists; D014361:Trypsin Inhibitors; D001464:Barium; D009538:Nicotine; D007611:Aprotinin; D013331:Strychnine; D010424:Pentobarbital; D000109:Acetylcholine; D001920:Bradykinin; D010433:Pentylenetetrazole; D004837:Epinephrine